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Analysing data  
from interviews  
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Colorectal	 5	 19	 3	 6	 8.3		
Upper	GI	 3	 10	 7	 6	 6	
Lung	 1	 13	 4	 2	 7	
Breast	1	 5	 12	 5	 9	 4	
Breast	2	 1*	 1	 1	 0	 1	
Prostate	 3	 5	 3	 7	 2.5	






























































































































































































































Extract:	1		 	 	 	 	 PAT45:	Fatigue	NRS	=	5;	FACIT-F	=	25	
VO45 – PAT45/DOC10  
DOC: all of that's o­ka::y (0.6) nothing giving you::? (0.6)  1	
too much [bo­ther  2	
PAT:         [­no::, (0.4) ­no: (.) ­um (0.4) the ­on­ly:  3	
 (1.0) u:::m (0.6) it’s (.) it’s the ­chemo:: [­that= 4	
DOC:                                              [hm ­mm 5	
PAT: =makes me ­ti:::red (ful-) tired all the time (0.4) .hhh 6	
which is the only symptom that’s, (0.4) >sort of< 7	

























Extract: 2.1	 	 	 	 	 	PAT07:	Fatigue	NRS	=	5;	FACIT-F	=	45 
VO07 – PAT07/DOC04  
DOC: .hhh (0.4) >how are you< doing,  1	
PAT: mm ­fai::r, (0.6) fai:r fair fai::r  2	
DOC: ¯okay (0.6) .hh describe fai::r,  3	
PAT: ­mm:::: (0.6) .hhh well the ­chemo knocks me ­fla:t (0.6)     4	
[­absol]utely knocks me flat (0.6) .hh u:::m,  5	
DOC: [°okay°]  6	
DOC: °°okay°° 7	
PAT: makes me feel very ­ill,  8	
DOC: o::h 9	
PAT: obviously, (0.4) a::nd (.) puts me off me ­foo:::d an-, 10	
(0.4) .hh and gives me funny tastes in me ­mouth ­and,  11	
(.) ­everything ­that, (0.4) ­they ­say in the ­boo::ks, 12	
(0.4) ­you ­­get (0.6) .hhh ­so:::: ­e:::rm ­­yeah   13	




PAT:       [e::::r]  15	
PAT: °­oo:f° (.) ­no not ­really, (0.6) >­I mean I< (0.4) get 16	
up early in the ­­morni::ng, (0.6) ­­yeah (0.6) ­not (.)  17	



















Extract:	2.2	 	 	 	 	 	PAT07:	Fatigue	NRS	=	5;	FACIT-F	=	45 
VO07 – PAT07/DOC04  
DOC: ­u::m, (2.8) okay (0.6) >I ­mea-< hhh (0.8) .tch ­how are 1	
you mana­ging with the chemo>therapy I mean< you say >it 2	
sort of< knocks you flat for five [da:ys ­afterwards  3	
PAT:                                    [well it ­does knock me  4	
flat (0.4) it ­makes you ­fee:l (0.4) pretty rough hhh 5	
(0.6) ­you kno:w  °­it's°  6	
DOC: okay (.) but it’s ­mo::re (0.6) .hhh it’s mo:re the (0.4)  7	
the not eating and the taste disturbance any ­sickness 8	
°­at ­­a:ll any ­nausea?°  9	
PAT:  ­u::::m, (0.6) I ­have been sick I wasn’t this ti:me 10	
      (0.6) <I: wa:s> sick the last time (0.6) they’re pretty 11	
16	lines	omitted:	the	patient	gave	an	account	of	receiving	anti-emetics,	having	mouth	ulcers	12	
and	his	experience	at	the	Day	Treatment	Unit	before	the	doctor	turned	away	to	write	notes	 13	
NUR:  but on those ­da::ys where you’re feeling so wiped out  14	
      are you literally in bed f- (0.4) [for a few days  15	
PAT:       [­yea::h I ju::st (.)                            16	
      go to bed and just sit, (.) sit (on it) I mean christmas  17	
      da::y >was a< (.) we ‘ad a two days £before christmas  18	
      da:(h):y£ and (?) 19	




PAT:  I was (.) flat on my ba:::ck  21	
DOC:  .hh is that because you fi:nd (0.4) getting out of bed to  22	
      be:: (0.6) diffi­cu::lt?  23	
PAT:  yea::h [it’s 24	
DOC:         [and up about 25	
PAT:  i::t er it’s just (layer) to lay sti:ll and lay ­flat  26	
      a:nd (0.6) let it (0.4) do whatever it’s got to ­do::  27	
      ­then (0.6) y’kno::w (.) after so many ­days you can  28	






















































Extract:	3	 	 	 	 	 	PAT33:	Fatigue	NRS	=	8.5;	FACIT-F	=	0	
VO33 – PAT33/DOC06  
00:00 DR: °mm° ­ha: good yea:h good to [see] you ­how ­have things= 1	
CR:                            [­mm]  2	
DR: =bee:n, [(?)     ] 3	
PT:         [not good] 4	




DR: .hh what ha- what have been the main problems,  9	
PT: ­over­whelmingly th- the sheer exhau::stion,  10	
DR: ri:gh[t, °okay°] 11	
PT:      [>I mean<] ­I’m spending ­more time ­sleeping during  12	
the day than I am a­wake, (0.6) .hhh um, (0.4) I just  13	
haven’t got an ounce of energy 14	
DR: °ri:ght° 15	
PT: no- not an [­ounce] of energy 16	












































Extract:	4	 	 	 	 	 	PAT53:	Fatigue	NRS	=	7;	FACIT-F	=	17	
VO53 – PAT01/DOC01 
DOC: °okay° (0.4) .hhh °ri:ght° (1.0) >any other symptoms< (.) 1	
er fa­ti::gue how’s that affecting you  2	
PAT: e::::rm, (0.6) we:ll i- it’s fa­tigue it’s making me feel 3	
tired er I ­can’t ­really::, (0.4) do very much I can sit 4	
up in a ­chai::r (0.4) ­for ­a, (0.4) period of time 5	
­bu:t,  6	
CAR: and that’s kind o::f (.) getting shorter and ­shorter 7	
tho:se periods >as I< sa:y ­just a (0.4) >for the< ­la:st 8	
­week I would sa::y just [e:r you’ve ­been ­really= 9	
PAT:                          [­mm::::   10	
CAR: =­really ­­wea::k,  11	




















Extract:	5	 	 	 	 	 	PAT53:	Fatigue	NRS	=	4;	FACIT-F	=	40	
VO01 – PAT01/DOC01  
DR: pre­su::me you’re feeling we:ll  1	
PT: ye:s, (0.4) ­ju:st I ­just (0.4) >I was< just saying to 2	
the: (.) ­cha:p I just get fa­ti::gued that’s all  3	
DR: how long does that last fo::r,   4	
PT: .hhh (0.6)  5	
CR:   all the time now  6	
PT: yea[::::h]  7	
CR:    [come on] be honest 8	
PT: yea:h 9	
CR: today she’s still tired and it’s two weeks after the 10	
event  11	
PT: yea:h, 12	
DR: oka:y   13	






















Extract:	6		 	 	 	 	 	PAT53:	Fatigue	NRS	=	5.5;	FACIT-F	=	12	
VO16 – PAT16/DOC
     DOC: ­fevers or high temperatu[res at all 1	
CAR:                          [no:e 2	
 (4.6)    3	
CAR: .hh but you’re very ­ti:red and, (0.4) all the time ­aint 4	
ya:: a::nd ­sleep a lot  5	
DOC: ri:ght 6	
PAT: ­o::h [¯yeah 7	
DOC:       [°okay°  8	













































Extract:	7		 	 	 	 	 	PAT49:	Fatigue	NRS	=	5;	FACIT-F	=	33	
VO49 – PAT49/DOC13 




PAT: .hhh I still feel tire::d (0.6) bu:t u::m, (0.6) ­­you 2	
­can cope with i::t >you know< ­have a little rest then 3	
sort of carry on an-  4	
DOC: .hh and how much time of the day are you:: (.) having 5	
rest  6	
PAT: hhhh (.) ­u:::m, (2.0) what (.) ¯we:ll (0.6) ­two or 7	
three times a ­day,  8	

















Extract:	8		 	 	 	 	 	PAT39:	Fatigue	NRS	=	5;	FACIT-F	=	25	
VO39 – PAT39/DOC09 (lines 1-16) 
10:30 DOC: .hhhhh (.) oka::y so ­that’s for your ­docto:r’s u::m,1	
  (0.4) reception to ge:t (.) some of tha:t (0.6) .hh now 2	
  ­what a­bout your energy levels ­how are tho::se.    3	
PAT: very low  4	
DOC: .hh ri::ght (0.40 [oka::y 5	
PAT:                   [­u:::m, (0.6) I ca- it’s not that I 6	
can’t ­do anythi:ng but as soon as I do: (1.0) I ­hav’n- 7	
got any::, (0.6) get up and [go   8	
DOC:                             [get up and go:::   9	
PAT: ­yeah  10	




PAT: not a lot [hu::h ha ha ha ha 12	
DOC:           [not a not very mu:ch >are ­you< ­just sitting 13	
around most of the da::y th[e::n  14	
PAT:                            [I’m afraid I ­a:m ye:s 15	
DOC: ri::ght o[kay  16	
CAR:          [you ­do ­try to go ou:t [every da:y  17	
PAT:                                   [I ­try to get ou:t for 18	
a wa:lk (0.6) [­even if i:t’s  19	













































































































Extract:	9		 	 	 	 	 PAT39:	Fatigue	NRS	=	4;	FACIT-F	=	29	
VO20 – PAT20/DOC01 (lines 44-69) 
DOC: I ­think we need to see how you get on with one dose at 1	
a:ll.  2	
CAR: ­fi:rst, 3	
DOC: and I think >if it< (.) ­rea::lly (.) knocks you for si:x 4	
(0.4) you should think about whether it’s the right thing 5	
to do or not  6	
PAT: ri:ght,  7	
CAR: okay  8	
PAT: ­yea:h  9	
DOC: cos it’s a­bout, (.) quality of li:fe  10	
CAR: it [is hhh  11	
PAT:    [­yeah 12	
DOC: and if ­having chemo destroys your quality of li:fe (0.6) 13	
for some po­tential future quality of life  14	
PAT: if you ­don’t have it, (0.6) mm- ­e::::r I mean are we 15	
biting the bullet and saying well ­that’s e:::r ­that’s 16	



































































Extract: 10		 	 	 	 	 PAT38:	Fatigue	NRS	=	4;	FACIT-F	=	41 
VO38 – PAT38/DOC03  
PT: I ­am quite tired I do get weary don’t I 1	
CR: mm,  2	
PT: ­u:::m (.) and I pre­sume that is the::: (0.6) effect of 3	
the chemo (.) no:t, (0.4) cancer (0.6) increasing o::r   4	
DR: ­­yep I would say that’s the effect of the chemo  5	
PT: [mm: 6	
DR: [and I ­think the wa:y you’re gonna ­fight tha:t (0.4) is 7	
by getting more active    8	
PT: ­ye:s  9	
DR: so::, (0.4) strange[ly enough 10	
PT:                    [see I ­ca:n overdo i:t, (.) hm 11	
DR: resting arou:nd (.) so lying around (0.4) [i:::s 12	
PT:                                           [doesn’t  13	
DR: doesn’t particularly help  14	
PT: well it’s al­right I’m not very good at  15	
[doing that ­so:: huh  16	
DR: [so, (.) ­do you did I say this last ­­ti:me? (0.4) half 17	
an hour of pulse raising exercise three times a week 18	
PT: ­oh ­no you didn’t say that  19	
DR: okay that’s [the target (0.4) that     20	




DR: that’s what’s been empirically sho­wn,  22	
PT: okay 23	
DR: to benefit (0.4) chemo related (.) u::m, (0.4) fati::gue 24	
PT: fatigue yeah, 25	
30	lines	omitted:	the	doctor	goes	on	to	further	explain	what	pulse	raising	exercise	is	and	
makes	an	enquiry	about	whether	she	has	a	dog	
PT: [well actually I ­do: enjoy my swimming (0.4) a:n[d  26	
DR:                                                  [yes 27	
PT: of course I’ve missed that having the PICC line and 28	
­every[thing   29	
DR:       [ye::s yeah  30	


















































































































































































































































































Extract:	11.1	 	 	 	 	 PAT45:	Fatigue	NRS	=	5;	FACIT-F	=	25	
VO45 – PAT45/DOC10 (lines 4-83) 
CAR: we’re just ha:lf the way throu:gh aren’t we .hh e:::r,  4	
DOC: .hhh [yea::h 5	
CAR:      [the initial (eightee:n)  6	
DOC: ­­so::::, (0.8) what ­tends to happen with chemotherapy 7	
>is you< get the ­best response early o::n (.) .hh and 8	
then as ­time goes o:::n (.) you: (.) you ge:t (.) a ­bit 9	
less response but people get (.) more tired (0.4) .hhhh 10	
a:nd, (0.4) run into more problems from it    11	
CAR: ­mm::.  12	
DOC: ­so:::, (0.4) er you ­had a great res­po:nse, (0.4) I 13	
would very much like to continue with your fourth cyc­le 14	
(0.4) if that’s [al­ri::ght? 15	
PAT:                 [°­mm°  16	
PAT: ­­mm::¯:: (0.4) su:re  17	
DOC: we should see you agai:n (0.4) in a month’s ti:­me (0.4) 18	
and depending on how you a::re (0.6) decide whether to go 19	
o:n (0.4) to a (0.4) a fifth cyc­­le (0.4) and likewise a 20	
sixth cycle [­I would say it i:s (0.4) pretty unusual=  21	
CAR:              [mm:::      22	
DOC: =(0.4) for me to give more than sixtee::n (1.0) dollops 23	
of chemo:: and [you’ve ha:d   24	
CAR:                [oh ri:ght 25	




DOC:    [ni:­:ne (0.4) .hh u:::m, (0.4) er >th- [the the<= 27	
CAR:                                            [mm::   28	
DOC: =­­absolute maximum anyone would twist ­my arm to is the 29	
eighteen that’s ­on the:re (0.4) .hhh I quite often stop 30	
between twelve and sixtee:n  31	
CAR: ri:ght  32	
DOC: ­s[o::: >i- it< depends how you’re ­­fee:li::ng, (0.4)= 33	
PAT:   [oka::y 34	
DOC: .hhh how it’s goi:ng, (1.8) >you know< ­and how you a::re  35	
PAT: ­o::h ­could you pick it up agai::n at some point in the 36	
futu::re if  37	
DOC: ­­­probably ­­try ­something ­else there are lots of 38	
[different ­treatments so:::, (.) it’s not that one= 39	
PAT: [oka::y, (.) ­ri:ght  40	
DOC: =couldn:’t it’s just that there are usually 41	
PAT: °okay° 42	
DOC: newe:r (0.4) b- [better different optio:ns 43	
PAT:                 [­ri:ght (.) ye:s  44	
PAT: yeah 45	
DOC: .hhhh um (.) so:::: (.) it’s im­portant that we don’t (.) 46	
wea:r you out so ­mu:ch  47	
PAT: .hhh hhh huh  48	
DOC: tha[:t (0.6) that [you really you know that (.) so it= 49	
CAR:    [mm:: 50	
PAT:                   [ye:s  51	
DOC: =­­it's ­­getting the balance ri:ght and ­we just need to 52	
decide that between us (0.4) .hhh as time goes o::n (0.6) 53	
.hhhhhh (0.8) al­though it’s scheduled fo::r, (0.8) week 54	
one week two week three (0.4) week o::ff (0.6) I’m ­very 55	
easy about tha:t ­so:::, (0.4) if ­you ­have something 56	
nice that you want a bit more ene[rgy fo::r   57	
CAR:                                  [mm  58	
CAR: °mm:::° 59	
DOC: have a (.) have a week off (0.6) and pick [it up agai:n= 60	
PAT:                                           [­oka::y  61	
DOC: =(0.4) a:fterwards >you know< as long as the nurses (0.6) 62	
>sort it out< and know when you’re coming (0.4) .hhh I 63	




CAR:                       [(°yea:h°  65	
DOC: =week o:n (0.4) week off (0.4) week o:::n 66	
PAT: .tch oka::y [that’s interesting (­fact)  67	
8	lines	omitted:	husband	enquires	if	the	breaks	in	treatment	are	to	help	the	immune	system	
DOC: a::nd, (0.6) .hhh (.) the chemotherapy’s about ­­treating 68	
the breast cancer which it’s doing really we:ll (0.6) but 69	
it’s also (.) ­got to be tolerab:le and give you good 70	
quality of life 71	
PAT: okay  72	
DOC: while you are on it .hhh a::nd, (0.6) par­ticularly in 73	
­this, (0.4) second ­ha::lf of the ­chemo::, (0.4) .hh if 74	




























Extract:	11.2	 	 	 	 	 PAT45:	Fatigue	NRS	=	5;	FACIT-F	=	25	
VO45 – PAT45/DOC10 (lines 142-155) 
 
DOC: u::m and actually we could always go ­back to the most 142	
important drug ­in the (­FE:C) (0.4) .hhh and give that 143	
week­ly,  144	
 (0.6)  145	
PAT: [ok[ay 146	
DOC: [u:[::m and there a:re (.) you know there are (.) ­lots 147	
of other  148	
CAR:    [mm:: 149	
PAT: ­that’s interesting 150	
DOC: goo:d  151	
PAT: hm ­mm, 152	
DOC: but, (.) ­le:ss (0.6) rug from under the ­feet, (0.4) 153	
















Extract:	11.3	 	 	 	 	PAT45:	Fatigue	NRS	=	5;	FACIT-F	=	25	
VO45 – PAT45/DOC10 (lines 179-222) 
DOC: it’s done we:ll (0.6) your liver’s working (0.4) 179	
brilliantly (0.6) we know it’s working in you (0.8) .hhh  180	
think we should continue:: (0.4) but I would  181	




PAT: [­mm (.) that’s fi::ne  183	
DOC: =.hh hh not [­only in terms of blood tests but also in= 184	
PAT:             [­OH YE::S  185	
DOC: =terms of [your energy levels (.) .hhh u:::m (0.4) a::nd= 186	
PAT:           [­mm::  187	
DOC: =[so::, (0.6) i- if it ­works that you (2.0)= 188	
CAR:  [mm::   189	
DOC: =go:: (0.6) week one week two week ­­off week one week 190	
week two week ­­off that’s fi:ne by ­me:: it ­really i:s 191	
(0.4) whateve::r,   192	
PAT: ­mm ¯mm: (0.8) ­well at the ­­mome:nt (0.4) ­i:t’s 193	
DOC: ­­brilliant  194	
PAT: ­quite tolerable (0.6) [ye:s 195	
17	lines	omitted:	the	doctor	orientates	to	the	quality	of	life	agenda	by	suggesting	they	may	
wish	to	celebrate	her	75th	birthday	with	a	family	party	or	go	away	for	a	weekend			
DOC: ­I’m, very happy for you to::, (0.6) jiggle with [the= 196	
CAR:                                                  [°ye:s° 197	
DOC: =[chemotherapy a bit   198	
PAT:  [­oka:y  199	
 (1.0) 200	
DOC: .hhhh (0.8) >cos it’s< (0.6) °you know° (0.4) .hhh  201	
CAR: ­we::, 202	
DOC: I ­can’t do much about the fati::gue (0.6) other tha::n, 203	
PAT: no:: [­I ­mea:n 204	





































































Extract:	12.1	 	 	 	 	 PAT39:	Fatigue	NRS	=	5;	FACIT-F	=	25	
VO39 – PAT39/DOC09 (lines 49-81) 
DOC: ­we:::ll, (0.4) >so there’s< no questio:n (0.6) that 49	
(0.4) what you’re fee::ling (0.6) is the side effects of 50	
the chemo­therapy:: (0.4) rather tha:n (0.6) the cancer 51	
causing the tiredne:ss (0.6) and the bowel problems and 52	
thi:ngs (0.6) >now the< ­question for u::s, (.) really 53	
i::s (0.4) .hh >you know< are you ­happy to con­tinue 54	
because the tiredness will get ­wo::rse (0.6) .hhh 55	
a::::nd, (0.6) I ­would say to you:: that (0.6) ­what, 56	
(0.4) the ti::me that we’re trying to buy for you:: (0.8) 57	
in­cludes the ti:me that you’re on ­treatme:nt (0.4) so 58	
it’s not about having the treatme:nt (0.4) being stuck in 59	
the house not being able to do anything and then having a 60	
li:fe ­­afterwa:rds it’s ­all about no:::w, (0.4) .hhhhh 61	
a::nd so the ­real question >is is whether< we: er (.) r- 62	
reduce the dru:g (.) do:se of the ­other two drugs (0.6) 63	
.tch to ­see: if >we can< keep make it a bit mo:re of a 64	




lo::t (0.4) .hhhh of ­treatme:nt I:: would be worrie:d 66	
(0.4) that you might end up >just doing< nothing at a:ll  67	
(1.6) 68	
PAT: .hhh [I have only got two to go    69	
DOC:      [and the fati::gue  70	
12:30  (2.0) 71	
PAT: [.hhh  e:::r 72	
DOC: [>but it< ­will hit you:: (.) I’ve seen it happen so: 73	
many times in situations like this whe:re .hhhh (0.4) 74	
>you know< how old are you sixty eight plus e::r  75	
[f- seventy tw- yea::h  76	
PAT: [seventy ­thr- seventy three   77	
DOC: so you kno:::w (.) >­i- it< is asking a lot of you at 78	
you're a::ge >to be able to< get through these (.) 79	
treatments completely and also at the fu:ll (.) dose:s 80	
(0.6) .hhh u::::m and you a::re (0.4) I think quite 81	
­sensi­tive to this (.) to this ­tablet chemotherapy:: 82	
(0.6) because it’s causi:ng (.) a lot m[ore proble:ms  83	
PAT:                                        [I I ­am still 84	



























Extract:	12.2	 	 	 	 	 PAT39:	Fatigue	NRS	=	5;	FACIT-F	=	25	
VO39 – PAT39/DOC09 (lines 96-132) 
DOC: ­so::: (.) ­­u::::m, (0.6) ­I’d ­I ­­personally:: fee:::l 96	
(0.4) that you’re probably better just to reduce the:: 97	
(0.6) the doses of the other two intre­venous drugs not 98	
the tablet o::ne, (0.4) so that everything is a::t (.) a 99	
slightly lowe::r (1.0) do::se to get you through the 100	
ne:xt  101	
PAT: ­okay 102	
DOC: next period of ­ti:me 103	
PAT: ­we::ll (.) I can only be guided by you on that  104	
[I can’t sa:y  105	
DOC: [yea::h  106	
 (0.6) 107	
DOC: .hhh ­some of the tiredness is partly becau::se (1.0) the 108	
chemotherapy’s probably affecting you:::r (0.6) blood 109	
counts (0.4) quite a lo::t (0.6) >it will be< 110	
­interesting to see:: whether you go ahead next week 111	
(0.6) [because it could be a- 112	
PAT:       [I su- um,      113	
PAT: I’ve booked m- (0.6) monday I’ve got a blood [test  114	
DOC:                                              [yea::h 115	
(0.4) .hh and and I (.) I h- I ­have found that people 116	
>who are starting to get< more tired on chemo­therapy:: 117	
(0.6) .hhh it’s partly becau::se (0.4) the white cell 118	
count has been affected mo::::re (.) on the chemo .hhhh 119	
(.) and quite ofte::n when they come up to the next 120	
­cycle (0.4) th- the body hasn’t quite re­cove:red (0.4) 121	






DOC:  and then we automatically have to reduce the dose 125	
­anywa::y,  126	
PAT: ­ye[s 127	
DOC:    [yea:h  128	
 (0.4) 129	





























































Extract: 13.1	 	 	 	 	 PAT48:	Fatigue	NRS	=	9;	FACIT-F	=	3 
VO48 - PAT48/DOC10 (lines 4-18) 
DOC: and then we:’ll,(0.6) come to a pla:::n about what we 4	
do:: (0.6) .hhhh [­um hhhh 5	
PAT:             [­well, (0.6) I’m pre­pared to try::: 6	
(0.6) the::, (0.6) capceta::n (0.6) at the lower do:se 7	




(.) bed for a ­wee:k (.) ­so ­be ­i::t, (0.8) ­u:::m, 9	
(0.6) w- you know (.) just curiosity see whether that 10	
lower dose of twe:lve, 11	
DOC: mm::,  12	
PAT: ­twelve ­hundred ­would ­e::r, (0.6) ­­would ­­do ­­it, 13	
(0.6) with­out upsetting me, (0.6) but I don’t know how 14	
you feel about that  15	
 (0.8) 16	
DOC: we::ll, (0.8) [thank you:: 17	









Extract: 13.2	 	 	 	 	 PAT48:	Fatigue	NRS	=	9;	FACIT-F	=	3 
VO48 - PAT48/DOC10 (lines 53-64) 
DOC: (0.6) ­giving ­you ­treatment (.) that knocks you do:wn 53	
so that you are, (0.6) ­­you ­­know hh (.) managi:ng, (.) 54	
bu:t,  55	
PAT: o::h 56	
DOC: but resting a bit more is ­reasonable 57	
PAT: mm 58	
(0.8) 59	




02:00 DOC: then knocking you down further is going to mean that (.) 64	
  you a:re absolutely ­bed ­bou:nd (0.4) .hhh and ­that’s 65	
  ­no- (0.4) ­that’s just not a safe thing to do::         66	
PAT: ­no::  67	
DOC: so:: (0.4) ­I don’t think at the mom­e::nt, (0.6) that 68	
<you:: a:::re> (0.4) ­well enou:::gh, (0.4) to (.) to 69	


















Extract:	13.3	 	 	 	 	 PAT48:	Fatigue	NRS	=	9;	FACIT-F	=	3	
VO48 - PAT48/DOC10 (lines 228-282) 
PAT: that might account for why I’m feeling particularly 228	
­li:mp this morning,  229	
 (1.6)  230	
DOC: .hh ­er at the moment you’re not fit fo:r (.0 for  231	
      chemothera[py 232	
PAT:           [­no I realise [that   233	
DOC:                          [>that that< would (0.6) just be 234	
dangerou:s 235	
PAT: mm  236	
(1.4) 237	
DOC: and I ­gue:::ss, (0.6) my con­ce::rn, (0.6) is tha:t 238	
(0.6) is whether you wi:ll (0.6) ­get to be fit for 239	
chemotherapy  240	
PAT: whether I will ge- 241	
DOC: whether you wi:::ll, (0.6) re­cover  242	
PAT: yeah 243	
DOC: from thi:s  244	
PAT: to have it   245	






DOC: taking ­ho:::ld,  249	
PAT: yes 250	
DOC: and whether you may not get (.) fit for [more treatment 251	
PAT:                                         [mm:::  252	
DOC: I’m ­not saying that we should (.) stop the exemes­ta::ne 253	
I think [­tha:t 254	
PAT:         [­no:  255	
DOC: you know 256	























































































































Extract:	14.1	 	 	 	 	 PAT33:	Fatigue	NRS	=	8.5;	FACIT-F	=	0	
VO33 – PAT33/DOC06 (lines 60-83) 
DR: .hhhh one of the things there is to try and take things 60	
i:n (0.6) >you know< a burst of activity and then a rest 61	
burst of activity, 62	
PT: mm: 63	
DR: but it, (.) doe:s (0.4) ­often you do have to tailor what 64	
you do:: (0.4) around ­what your energy levels a:re,  65	
PT: yeah  66	
DR: I’m a­fraid it is a question of adapting [to the:] (.)=  67	
PT:                                          [yeah,  ] 68	
DR: =>you know the am[ount] of energy [that’s] there .hhh  69	
PT:                  [yeah]           [yeah, ] 70	
PT: and I mean I (­take it) there’s nothing that can be ­done 71	
to alleviate #tha::t# 72	
DR: w- we’ll have a look through the tablets, because 73	
some­ti::mes, (0.4) changing steroids and things like 74	
























Extract:	14.2	 	 	 	 	 	PAT33:	Fatigue	NRS	=	8.5;	FACIT-F	=	0	
VO33 – PAT33/DOC06 (lines 7-31) 
 
DOC: ­tiredness is quite a difficult one I’m afraid becau:se  1	
u:::m, (0.6) there ­isn’t a single tablet that will >sort 2	
of< get rid of it (0.4) .hhh (1.0) people have looked at 3	
things like stimula::nts, (0.6) >you know< to see if that 4	
does he:lp but (.) ­they ­they haven’t really been of 5	
bene[fi:t 6	
PAT:     [­no: no 7	
DOC: but ­one ­of ­the ­things we ­do: find sometimes >is 8	
that< if (.) the prednisolo:ne he::lped (0.6) which it 9	
did originally  10	
PAT: mm 11	
DOC: sometimes a slightly more potent steroid called 12	
dexamethaso::ne (0.4) can be a bit more effective  13	
PAT:  ­oh ­ri:ght  14	
      DOC:  and I think it’s ­worth trying tha::t (.) instead of the   15	
            prednisolo:ne (0.6) .hhh and see if that actually helps   16	
            with your appetite a bit [and with the:: 17	
PAT:                           [oka::y   18	
DOC:  .hhh it vir- (0.4) virtually always goes together so the  19	
      ­tiredness and the poor appetite  20	
PAT:  °yeah° 21	
DOC:  they virtually always go together 22	
PAT:  yeah 23	
DOC:  a:::nd er  24	





































































































































































Code	 Pseudonym		 Sex	 Age	 Diagnosis	 Occupation	
PI01VO01	 Sharon		 Female	 67	 Colorectal	 Retired	
PI02VO04	 Stephen	 Male	 54	 Colorectal		 Self-employed		
PI03VO03	 Cecil	 Male	 74	 Colorectal	 Retired	
PI04VO05	 Michael	 Male	 59	 Colorectal	 Retired		
PI05VO08	 Conor	 Male	 59	 Colorectal	 Retired	
PI06VO07	 Gordon	 Male	 60	 Pancreatic		 Self-employed	
PI07VO18	 Brian	 Male		 68	 Pancreatic	 Retired	
PI08V020	 Clive	 Male	 81	 Colorectal	 Retired	
PI09V022	 Eileen	 Female	 93	 Colorectal	 Retired	
PI10VO29	 Shay	 Male	 69	 Colorectal	 Retired	
PI11VO26	 Claire	 Female	 67	 Lung	 Retired	
PI12VO28	 Sonya	 Female	 75	 Colorectal	 Retired	
PI13VO31	 Daniel	 Male	 82	 Mesothelioma	 Retired	
PI14VO35	 Larry	 Male	 85	 Lung	 Retired	
PI15VO39	 Tom	 Male	 73	 Oesophageal	 Retired	
PI16VO38	 Pandora	 Female	 59	 Colorectal	 Paid	work	
PI17VO48	 Jane	 Female	 67	 Breast	 Retired	
PI18VO44	 Chloe	 Female	 66	 Breast	 Retired		
PI19VO46	 Clodagh	 Female	 47	 Breast	 Paid	work	
PI20VO43	 Peggy	 Female	 68	 Breast	 Retired	
PI21VO45	 Gloria	 Female	 75	 Breast	 Retired		







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Code	 Sex	 Grade	 Specialty	
CI01	 Male	 Specialist	Registrar		 Medical	Oncology	
CI02	 Female	 Clinical	Research	Fellow		 Clinical	Oncology	
CI03	 Male	 Consultant		 Medical	Oncology	
CI04	 Female	 Consultant	 Medical	Oncology	
CI05	 Female	 Consultant		 Clinical	Oncology	
CI06	 Male	 Consultant		 Clinical	Oncology	
CI07	 Female		 Consultant		 Medical	Oncology	
CI08	 Male	 Consultant	 Medical	Oncology	































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Oxford Brookes University 
 
Faculty of Health and Life Sciences 
 





The Departmental Research Ethics Officer (DREO) / Faculty Research Ethics Committee (FREC) 
has considered the application for ethics approval for the following project: 
 
Project Title: A mixed methods study exploring patients’ and doctors’ attitudes to fatigue in 
advanced cancer and chronic heart failure and how they communicate this symptom 
 
FREC Study Number: 2013/16 
 
Name of Applicant: Dr John Curtin 
 
Name of Supervisor: Dr Helen Walthall 
             
   Please tick one box 
 
1. The Faculty Research Ethics Committee gives ethical approval for the research  
project. 
 
Please note that the research protocol as laid down in the application and hereby 
approved must not be changed without the approval of the DREO / FREC 
 
 
2. The Departmental Research Ethics Officer / Faculty Research Ethics Committee  





3. The Departmental Research Officer / Faculty Research Ethics Committee   
cannot give ethical approval for the research project.  The reasons for  
this and the action required are as follows: 
 
 
Signed: …Hazel Abbott … ………………………   Approval Date: ………2nd May 2014........…… 
 
 
Designation: Departmental Research Ethics Officer  
 
(Signed on behalf of the Faculty Research Ethics Committee) 
 
 





































































































Clinician Information Sheet 







We want to understand what happens within the consultation between the patient and the 
doctor, specifically surrounding the communication of cancer or heart failure symptoms     (e.g. 
breathlessness, fatigue or pain) and how they are addressed by doctors. Some patient surveys 
suggest that some symptoms which are important to patients, such as fatigue, are sometimes 
not addressed within the consultation. We want to understand what is important to patients 
and see if we can identify ways to improve communication between doctors and patients. This 
can be best explored by videoing consultations and separately interviewing patients and 
doctors. The study will not evaluate individual job performance. 
The first part of the study will involve video-recording 60 - 100 consultations between doctors 
and patients, at a number of oncology and heart failure outpatient clinics in several hospitals. 
If you take part in this study, your appointments with patients who give consent during the 
study period will be audio and video recorded. Patients will be asked to arrive 10 minutes early 
for their appointment and the consent process should not delay their scheduled appointment. 
The patient’s companion(s), any person(s) who attends the consultation with the patient, are 
considered participants in this study and will also sign a consent form. 
The camcorder and audio recorder are very discreet and research has shown that this should 
not interfere with the consultation. I will set up the equipment prior to the appointment and 
start the recording when you are ready. I will not be present when you see the patient. The 
camcorder will not record physical examination and the lens can be covered with a screen if 
necessary. I will show you how to do this. 
I will show all participants how to turn off the camcorder in case any participant wishes to stop 
the recording at any time and for any reason. After the consultation, I will ask you all if you are 
happy for your recording to be used in the research study. If any participant is unhappy with 
it, I will delete the recording immediately.   
My name is John Curtin and I am a PhD student at Oxford Brookes University. I am also a 
specialist trainee in palliative medicine on approved out of programme research experience 
from the XXXXXXXX Deanery.  
In association with the Oncology and Heart Failure clinical teams at XXXXXXXXXXX NHS 
Trust, we are conducting a research study about outpatient consultations in the hospital. This 
research study will contribute towards my PhD thesis. 


















Why are appointments being video-recorded?  
We need to record appointments in order to capture the details of what is said and how it is said. 
It is impossible to do this just by observing and making notes or by asking cardiologists about 
their work. We want to video-record in particular, because it helps us to record both verbal and 
non-verbal communication. 
 
The second part of the study involves interviewing patients and doctors separately some days 
to weeks after the recorded consultation. Patients with fatigue, as measured by a validated 
assessment tool, will be interviewed in their own home. Consultant oncologists or cardiologists, 
including specialist trainees with at least 2 years’ experience, will be interviewed at a convenient 
place and time. The semi-structured interview will last between 20 and 40 minutes. We hope to 
interview 30 to 40 clinicians.  
If you wish to hear more about the study or wish to take part, please contact me on the details at 
the end of this information sheet. If you agree to take part, I will ask you to sign a consent form at 
a time that is convenient, prior to your outpatient clinic. Consent will last for the duration of the 
study, which we expect will be for 12 months.  
 
What are the possible benefits of taking part? 
We hope the study may help to improve the assessment and management of symptoms in 
patients with cancer or heart failure. Subject to each participant’s consent, it is possible that your 
recordings could be used for the training and teaching of students and healthcare professionals. 
If you wish, the findings of the study will be fed back to you in written form and where possible, 
will be presented at departmental or network research meetings.  
What are the possible disadvantages of taking part? 
We do not foresee any risks to doctors taking part, other than it will take up some of your time. 
The recordings of consultations will be used only for the purposes of this research. You should 
also be aware that I am a registered doctor with the General Medical Council and I am bound by 
the professional duties of a doctor by this professional body. If something of concern is observed 
or reported during the research study then the researcher has a duty to report this. 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time. Any information collected during the time that 
















What will be done with the information collected in the study? 
The recordings will be analysed by researchers at Oxford Brookes University, Loughborough 
University and Portland State University. Subject to consent, the findings will be published in 
scientific journals, presented at conferences and in training workshops. All quotes will be 
anonymous and your name will never be included in any paper or presentation.   
 
Will my taking part in the study be confidential? 
All information that is collected about you (video and audio recordings and transcripts) will be 
handled and kept strictly confidential, and any information about you will have your name removed 
so that you cannot be recognised. Once the data has been collected, code numbers or false 
names will be used in place of real names. Your data can only remain confidential within the 
limitations of the law. All members of the research and transcribing teams have a duty to protect 
your confidentiality. Audio recordings only will be sent to a professional transcribing team. Nothing 
that could reveal your identity will be disclosed beyond these teams. 
Transcripts of your recordings and consent forms will be kept by the research team (John Curtin 
and Dr Helen Walthall) and stored securely in locked cupboards in a locked office at Oxford 
Brookes University. Your recordings will be stored on a password protected computer and access 
will be restricted to named research team members. Your recordings may be shared outside of 
the European Economic Area (EEA), as one of the research team           (Dr Jeffrey Robinson) is 
based in Portland State University, USA. No patient identifying details will accompany your 
recordings. Dr Robinson is bound by the National Institute for Health in the USA, to adhere 
to excellent data protection standards and so all data will remain confidential. 
All information that is collected about you will be kept for 20 years for the purposes of writing up 
the study’s findings for publication and in order that the data can be reanalysed. After 20 years, 
all your information will be destroyed. No individual participants will be identified when the results 
of the study are published.   
With your permission, we may show small clips from your audio or video recordings to other 
researchers at meetings, or use them for teaching or in the training of clinicians. If we play any 
clips from the recordings at meetings they will be very short, typically less than a minute. With 
your permission, we may use your recordings for other research projects or share with other 
research teams. Your confidentiality will be protected at all times.  
Oxford Brookes University will act as data controller of the study and the data collected is for 
research purposes only. The University has no intention of causing harm or distress to any 



















Who is organising and funding the study? 
The research is funded by Oxford Brookes University. The research team includes 
researchers from Oxford Brookes University and Loughborough University. The study has 
been approved by both the Oxford Brookes University Faculty Research Ethics Committee 
and the XXXXXXXXXXX NHS Research Ethics Committee.  
 
If you have any questions about the study, please don’t hesitate to contact:   
 
Dr John Curtin, PhD student, Faculty of Health and Life Sciences, Oxford Brookes University 
 
Telephone: 01865 485278 or email: john.curtin-2013@brookes.ac.uk 
 
 
If you wish to raise questions about how the research is being conducted or complain 
formally, you can contact:  
 
Hazel Abbott, Departmental Research Ethics Officer, Faculty of Health and Life Sciences  
 
Telephone: 01865 482639 or email: heabbott@brookes.ac.uk 
 
 
Research and academic supervisory team from Oxford Brookes University includes:  
 
Dr Helen Walthall, Principal Lecturer, Faculty of Health and Life Sciences 
 
Prof Eila Watson, Professor in Supportive Cancer Care, Department of Clinical Health Care 
 
Dr Bee Wee, Consultant and Senior Lecturer in Palliative Medicine, Sobell House,  
Oxford University Hospitals NHS Trust 
 
Research and academic team from Loughborough University includes:  
 
Prof Paul Drew, Professor of Conversational Analysis, Department of Social Sciences 
 
Research and academic team from Portland State University, Oregon, USA includes:  
 
Dr Jeffrey Robinson, Professor of Communication, Department of Communication 
 
 















Appendix	3.4			Patient	Information	Sheet	–	Part	A																																																												                                                            	
 
Patient Information Sheet 
A study of communication about symptoms in Outpatient Clinics 
 









This information sheet tells you about the study. Please read it carefully and ask me if there is 
anything that is not clear or if you would like more information. Please take time to decide 
whether or not you wish to take part. Many thanks for reading this.  
What is the purpose of this study?  
We want to understand what happens within the consultation, the interaction between a patient 
and doctor in a hospital appointment, specifically surrounding the communication of cancer or 
heart failure symptoms (e.g. breathlessness, fatigue or pain) and how they are addressed by 
doctors. Research has shown that some symptoms that are important to patients, such as 
fatigue (tiredness, exhaustion or low energy levels), are sometimes not discussed in the 
consultation. We want to understand what is important to patients and see if we can identify 
ways to improve communication between doctors and patients.  
Why have I been invited? 
This research study includes patients with a diagnosis of cancer or heart failure. You have 
been invited to take part because you have an appointment with a cancer or heart specialist 
who has agreed to take part in this study. We hope that around 60 - 100 patients who attend 
the cancer or heart failure clinics at the hospital will take part in this study.   
 
 
My name is John Curtin and I am a PhD student at 
Oxford Brookes University. In association with the 
Cancer and Heart Failure clinical teams at 
XXXXXXXXXXXXX NHS Trust, we are conducting a 
research study about patient-doctor consultations, in 
the outpatient clinic of the hospital. This research 
study will contribute towards my PhD thesis.  
Thank you for considering taking part in this study.	
Before you decide, it is important for you to 
understand why the research is being done and what 






















Do I have to take part? 
No, it is entirely up to you. This information sheet should help you to decide whether you want to 
take part and we are happy to answer any questions you may have. If you wish to hear more 
about the study, please complete and return the reply slip at the end of this information sheet. I 
would then meet with you before your next appointment to explain the study further. This request 
for further information would not commit you to take part in the study. Even if you were to opt 
in, you would be free to leave at any time. A decision to leave the study or to decline to be 
involved would not affect the standard of care you receive from the clinical team.    
What will happen to me if I take part? 
If you would like to hear more about the study, please complete and return the reply slip in the 
stamped addressed envelope provided. I will meet you in the waiting area of the outpatient clinic 
after you have checked in with the receptionist. Please come 10 minutes early for your 
appointment. I will describe the study and go over the information sheet with you and ask if you 
have any questions. When you think I have answered all your questions and if you agree to 
continue, I will ask you to sign a consent form. You are free to change your mind at any time. 
After this, you will have your consultation with the specialist which will be just like normal except 
that I will audio and video record it. The recording equipment will be set up before the appointment 
so that I will not be present while you talk with the doctor. This gives you privacy. The camcorder 
and audio recorder are very discreet and most people forget they are being recorded. Apart from 
the recording, your appointment will be no different to what would have happened with the 
specialist if you were not taking part in the study. The camcorder will be left on throughout your 
appointment and will record the conversation between you and your doctor. The camcorder will 
not record physical examination and the lens can be covered with a screen if necessary.   
I will show you how to turn off the camcorder in case you wish to stop the recording at any time 
and for any reason. After the consultation, I will ask you if you still agree for your recording to be 
used in the research study. If you are unhappy with it, I will delete the recording immediately.   
After the consultation I will ask you to fill in a questionnaire that will take less than 10 minutes to 
complete. You are free to not answer any question. I will also ask you less than 5 questions about 
your general activity and symptoms (breathlessness and fatigue) in the preceding week.  
There is a second part of this study, an interview study with some of the patients who had their 
consultation recorded. You might or might not be invited to this follow-up interview study after 

















Why are appointments being recorded? 
We would like to see how doctors and patients communicate during a consultation and how 
common symptoms are discussed and managed. Video-recording provides us with the 
opportunity to observe what is discussed without being present and is therefore less intrusive for 
both the patient and doctor. It also helps us to know, for example, what is happening in silences 
during the consultation (e.g. did someone nod or smile or shake their head). 
What will I have to do? 
If you decide to take part, you will be asked to sign a consent form. After your appointment I will 
ask you to complete a short questionnaire and ask you a few questions, that in total will take less 
than 10 minutes.  
What are the possible benefits of taking part? 
The study may not have any direct benefits for you but it is hoped that the findings will help doctors 
to provide better support for patients in the future. The findings of the study may help doctors to 
improve the assessment and management of symptoms in cancer or heart failure. 
What are the possible disadvantages of taking part? 
There is a small chance that you might feel uncomfortable about having your appointment video-
recorded. At any time, you are free to turn off the camcorder or ask for the recording to be stopped. 
There is also a small chance that you might find some questions difficult to answer in the 
questionnaire. In this case you are free not to answer a question.   
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time without your standard of care being affected in any 
way. Any information collected during the time that you took part will be destroyed and your 
confidentiality will continue to be protected. This means that the video-recording of the 
consultation will be deleted and your questionnaire responses will be shredded. In addition, where 
possible, your data that has been destroyed will be confirmed in writing. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions (on phone number 01865 485278). If you remain 
unhappy and wish to raise questions about how the research is being conducted, you can contact 
Hazel Abbott, Departmental Research Ethics Officer, Faculty of Health and Life Sciences on 
01865 482639. If you remain unhappy and wish to complain formally, you may also follow the 
normal NHS complaints procedure. Please see: 

















What will be done with the information collected in the study? 
The recordings and the questionnaire responses will be examined by researchers at Oxford 
Brookes University, Loughborough University and Portland State University. The findings will be 
used to develop guidelines on how best to assess symptoms in the clinic. The findings will also 
be published in scientific journals and presented at conferences and in training workshops. With 
your permission, we may use direct quotes from your appointment with the specialist in these 
papers, presentations and workshops. However, the quotes will be anonymous and your name 
will never be included in any paper or presentation. If you wish, we will send you a summary of 
the findings at the end of the study. This will be in about two years’ time. 
Will my taking part in the study be confidential? 
All information that is collected about you (video and audio recordings, transcripts and 
questionnaires) will be handled and kept strictly confidential, and any information about you will 
have your name and address removed so that you cannot be recognised. Once the data has been 
collected, code numbers or false names will be used in place of real names. Your data can only 
remain confidential within the limitations of the law. All members of the research and transcribing 
teams have a duty to protect your confidentiality. Audio recordings only will be sent to a 
professional transcribing team. Nothing that could reveal your identity will be disclosed beyond 
these teams. 
Transcripts of your recordings, questionnaires and consent forms will be kept by the research 
team (John Curtin and Dr Helen Walthall) and stored securely in locked cupboards in a locked 
office at Oxford Brookes University. Your recordings will be stored on a password protected 
computer and access will be restricted to named research team members. Your recordings may 
be shared outside of the European Economic Area (EEA), as one of the research team (Dr Jeffrey 
Robinson) is based in Portland State University, USA. No patient identifying details will 
accompany your recordings. Dr Robinson is bound by the National Institute for Health in the USA, 
to adhere to excellent data protection standards and so all data will remain confidential. 
All information that is collected about you will be kept for 20 years for the purposes of writing up 
the study’s findings for publication and in order that the data can be reanalysed. After 20 years, 
all your information will be destroyed. No individual participants will be identified when the results 
of the study are published.   
With your permission, we may show small clips from your audio or video recordings to other 
researchers at meetings, or use them for teaching or in the training of clinicians. If we play any 
clips from the recordings at meetings they will be very short, typically less than a minute. With 
your permission, we may use your recordings for other research projects or share with other 
research teams. Your confidentiality will be protected at all times. 
Oxford Brookes University will act as data controller of the study and the data collected is for 
research purposes only. The University has no intention of causing harm or distress to any 

















Who is organising and funding the study? 
The research is funded by Oxford Brookes University. The research team includes researchers 
from Oxford Brookes University, Loughborough University and Portland State University.  
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been approved by both the Oxford Brookes 
University Faculty Research Ethics Committee and the XXXXXXXXXX NHS Research Ethics 
Committee.  
Who should I contact with questions? 
If you have any questions about the study, please don’t hesitate to contact:   
 
John Curtin, PhD student, Faculty of Health and Life Sciences, Oxford Brookes University  
 
Telephone: 01865 485278 or email: john.curtin-2013@brookes.ac.uk 
 
 
Research and supervisory team from Oxford Brookes University includes:  
 
Dr Helen Walthall, Principal Lecturer, Faculty of Health and Life Sciences 
 
Prof Eila Watson, Professor in Supportive Cancer Care, Department of Clinical Health Care 
 
Dr Bee Wee, Consultant and Senior Lecturer in Palliative Medicine, Sobell House,  
Oxford University Hospitals NHS Trust 
 
Research and academic team from Loughborough University includes:  
 
Prof Paul Drew, Professor of Conversational Analysis, Department of Social Sciences 
 
Research and academic team from Portland State University, Oregon, USA includes:  
 
Dr Jeffrey Robinson, Professor of Communication, Department of Communication 
 
 
























From: Hazel Abbott <heabbott@brookes.ac.uk>
Subject: Re: Update of experience of recruitment with study: FREC 2013/16; 
REC 14/SC/1185
Date: 4 December 2014 at 11:43:09 GMT
To: John Curtin <john.curtin-2013@brookes.ac.uk>
Dear John,
 
Many thanks for this update.  Yes, I think that this approach falls within the 
boundaries of your ethics approval and good practice.  You have emphasised the 
consensual nature of taking part to potential participants and taken steps to 
ensure they have time to consider and then re-consider participation.  If the 
approach proposed is at the potential participant's request and makes 





On 1 December 2014 at 15:17, John Curtin <john.curtin-2013@brookes.ac.uk> 
wrote:
Dear Hazel,
I just wanted to update you on my experiences of recruiting patient participants 
for my study in order to ensure that I am staying within best ethical practice and 
the ethical boundaries of my FREC/ NRES approval. 
I informed you recently that some patients prefer to give me their contact details 
and want to be contacted by me prior to their appointment. They give their 
information voluntarily (as they would on the Reply Slip if they posted it back to 
me). I understand ethically this is fine as participants are directing the researcher.
Some patients are very keen to partake in the study and direct me that they wish 
to meet me at their next appointment. I then suggest that they need to read the 
PIS form carefully and think about it etc. These patients frequently direct me to 
complete the Reply Slip with me in the clinic rather than post it back to me as this 
is too much of a burden. I want to ask if ethically this similar to our earlier 
discussion and that they are similarly directing the researcher? 
When we complete the Reply Slip together, I emphasise that it is completely 
optional that they give me their contact details. If they wish to give me their 
contact details, then I suggest the reasons why this might be helpful so that I 
could contact them before their appointment to ensure that they are still happy to 
meet with me or well enough to partake in the study or well enough to attend the 
clinic. 

















Patient’s Companion Information Sheet 
A study of communication about symptoms in Outpatient Clinics 
 









This information sheet tells you about the study. Please read it carefully and ask me if there is 
anything that is not clear or if you would like more information. Please take time to decide whether 
or not you wish to take part. Many thanks for reading this.  
What is the purpose of this study?  
We want to understand what happens within the consultation, the interaction between a patient 
and doctor in a hospital appointment, specifically surrounding the communication of cancer or 
heart failure symptoms (e.g. breathlessness, fatigue or pain) and how they are addressed by 
doctors. Research has shown that some symptoms that are important to patients, such as fatigue 
(tiredness, exhaustion or low energy levels), are sometimes not discussed in the consultation. We 
want to understand what is important to patients and see if we can identify ways to improve 
communication between doctors and patients.  
Why have I been invited? 
We have invited you to take part because you will be accompanying the patient to an appointment 
with a cancer or heart specialist who has agreed to take part in this study. We hope that around 
60 - 100 patients who attend the cancer or heart failure clinics will take part in this study.   
	
My name is John Curtin and I am a PhD student at 
Oxford Brookes University. In association with the 
Cancer and Heart Failure clinical teams at 
XXXXXXXXXX NHS Trust, we are conducting a 
research study about patient-doctor consultations, in 
the outpatient clinic of the hospital. This research 
study will contribute towards my PhD thesis.  	
Thank you for considering taking part in this study.	
Before you decide, it is important for you to 
understand why the research is being done and what 

















Do I have to take part? 
No, it is entirely up to you. This information sheet should help you to decide whether you want to 
take part and we are happy to answer any questions you may have. If you wish to hear more 
about the study, please complete and return the reply slip at the end of this information sheet. I 
would then meet with you and the patient before their next appointment to explain the study 
further. This request for further information would not commit you to take part in the study. Even 
if you were to opt in, you would be free to leave at any time. A decision to leave the study or 
to decline to be involved would not affect the standard of care that the patient receives from the 
clinical team.    
What will happen to me if I take part? 
If you would like to hear more about the study, please complete and return the reply slip in the 
stamped addressed envelope provided. I will meet you and the patient in the waiting area of the 
outpatient clinic after you have checked in with the receptionist. Please come 10 minutes early 
for the appointment. I will describe the study and go over the information sheet with both of you 
and ask if you have any questions. When you think I have answered all your questions and if you 
agree to continue, I will ask both of you to sign a consent form. You are free to change your mind 
at any time. 
After this, the patient will have their consultation with the specialist which will be just like normal 
except that I will audio and video record it. The recording equipment will be set up before the 
appointment so that I will not be present while both of you talk with the doctor. This gives you 
privacy. The camcorder and audio recorder are very discreet and most people forget they are 
being recorded. Apart from the recording, the appointment will be no different to what would have 
happened with the specialist if you were not taking part in the study. The camcorder will be left on 
throughout the appointment and will record the conversation between you and the doctor. The 
camcorder will not record physical examination and the lens can be covered with a screen if 
necessary.   
I will show both of you how to turn off the camcorder in case you wish to stop the recording at any 
time and for any reason. After the consultation, I will ask you if you still agree for your recording 
to be used in the research study. If you are unhappy with it, I will delete the recording immediately.   
After the consultation I will ask the patient to fill in a questionnaire that will take less than 10 
minutes to complete. The patient is free to not answer any question. I will also ask the patient less 
than 5 questions about their general activity and symptoms (breathlessness and fatigue) in the 
preceding week.  
There is a second part of this study, an interview study with some of the patients who had their 
consultation recorded. The patient might or might not be invited to this follow-up interview study 


















Why are appointments being recorded? 
We would like to see how doctors and patients communicate during a consultation and how 
common symptoms are discussed and managed. Video-recording provides us with the 
opportunity to observe what is discussed without being present and is therefore less intrusive for 
both the patient and doctor. It also helps us to know, for example, what is happening in silences 
during the consultation (e.g. did someone nod or smile or shake their head). 
What will I have to do? 
If you decide to take part, you will be asked to sign a consent form. After the patient’s appointment, 
I will ask the patient to complete a short questionnaire and ask them a few questions that in total 
will take less than 10 minutes.  
What are the possible benefits of taking part? 
The study may not have any direct benefits for the patient but it is hoped that the findings will help 
doctors to provide better support for patients in the future. The findings of the study may help 
doctors to improve the assessment and management of symptoms in patients with cancer or heart 
failure. 
What are the possible disadvantages of taking part? 
There is a small chance that you or the patient might feel uncomfortable about having the 
appointment video-recorded. At any time, you or the patient are free to turn off the camcorder or 
ask for the recording to be stopped.  
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time without the standard of care of the patient being 
affected in any way. Any information collected during the time that you took part will be destroyed 
and your confidentiality will continue to be protected. This means that the video-recording of the 
consultation will be deleted. In addition, where possible, your data that has been destroyed will 
be confirmed in writing. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions (on phone number 01865 485278). If you remain 
unhappy and wish to raise questions about how the research is being conducted, you can contact 
Hazel Abbott, Departmental Research Ethics Officer, Faculty of Health and Life Sciences on 
01865 482639. If you remain unhappy and wish to complain formally, you may also follow the 
normal NHS complaints procedure. Please see: 


















What will be done with the information collected in the study? 
The recordings and the questionnaire responses will be examined by researchers at Oxford 
Brookes University, Loughborough University and Portland State University. The findings will be 
used to develop guidelines on how best to assess symptoms in the clinic. The findings will also 
be published in scientific journals and presented at conferences and in training workshops. With 
your permission, we may use direct quotes from the patient’s appointment with the specialist in 
these papers, presentations and workshops. However, the quotes will be anonymous and your 
name will never be included in any paper or presentation. If you wish, we will send you a summary 
of the findings at the end of the study. This will be in about two years’ time. 
Will my taking part in the study be confidential? 
All information that is collected about you (video and audio recordings and transcripts) will be 
handled and kept strictly confidential, and any information about you will have your name and 
address removed so that you cannot be recognised. Once the data has been collected, code 
numbers or false names will be used in place of real names. Your data can only remain 
confidential within the limitations of the law. All members of the research and transcribing teams 
have a duty to protect your confidentiality. Audio recordings only will be sent to a professional 
transcribing team. Nothing that could reveal your identity will be disclosed beyond these teams. 
Transcripts of your recordings and consent forms will be kept by the research team (John Curtin 
and Dr Helen Walthall) and stored securely in locked cupboards in a locked office at Oxford 
Brookes University. Your recordings will be stored on a password protected computer and access 
will be restricted to named research team members. Your recordings may be shared outside of 
the European Economic Area (EEA), as one of the research team           (Dr Jeffrey Robinson) is 
based in Portland State University, USA. No patient identifying details will accompany your 
recordings. Dr Robinson is bound by the National Institute for Health in the USA, to adhere 
to excellent data protection standards and so all data will remain confidential. 
All information that is collected about you will be kept for 20 years for the purposes of writing up 
the study’s findings for publication and in order that the data can be reanalysed. After 20 years, 
all your information will be destroyed. No individual participants will be identified when the results 
of the study are published.   
With your permission, we may show small clips from your audio or video recordings to other 
researchers at meetings, or use them for teaching or in the training of clinicians. If we play any 
clips from the recordings at meetings they will be very short, typically less than a minute. With 
your permission, we may use your recordings for other research projects or share with other 
research teams. Your confidentiality will be protected at all times. 
Oxford Brookes University will act as data controller of the study and the data collected is for 
research purposes only. The University has no intention of causing harm or distress to any 


















Who is organising and funding the study? 
The research is funded by Oxford Brookes University. The research team includes 
researchers from Oxford Brookes University, Loughborough University and Portland State 
University.  
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been approved by both the Oxford 
Brookes University Faculty Research Ethics Committee and the XXXXXXXXXXXX NHS 
Research Ethics Committee.  
Who should I contact with questions? 
If you have any questions about the study, please don’t hesitate to contact:   
 
John Curtin, PhD student, Faculty of Health and Life Sciences, Oxford Brookes University 
 
Telephone: 01865 485278 or email: john.curtin-2013@brookes.ac.uk 
 
 
Research and supervisory team from Oxford Brookes University includes:  
 
Dr Helen Walthall, Principal Lecturer, Faculty of Health and Life Sciences 
 
Prof Eila Watson, Professor in Supportive Cancer Care, Department of Clinical Health Care 
 
Dr Bee Wee, Consultant and Senior Lecturer in Palliative Medicine, Sobell House,  
Oxford University Hospitals NHS Trust 
 
Research team from Loughborough University includes:  
 
Prof Paul Drew, Professor of Conversational Analysis, Department of Social Sciences 
 
Research and academic team from Portland State University, Oregon, USA includes: 
 
























Patient Consent Form 
A study of communication about symptoms in Outpatient Clinics 
 
                              Please write your initials in the relevant boxes: 
(only initial those boxes where you agree to what is being asked)  
 
 
1.  I confirm that I have read and understand the information sheet for the above  
     study, that I have had the opportunity to ask questions and have had these 
     answered satisfactorily. 
 
2.  I understand that my participation is voluntary and that I am free to withdraw at  
     any time, without giving reason. 
 
3.  I agree to my consultation with the specialist being video and audio recorded.  
 
 
4.  I agree to complete the questionnaire on the understanding that I can choose  
     not to answer some questions.   
 
5.  I understand that by taking part, I am agreeing that the research team can obtain  
     information from my Consultant in relation to the diagnosis and treatment plan        
     of my illness. 
 
6.  I understand that relevant sections of my medical notes and data collected  
     during the study, may be looked at by individuals from the research team, from  
     regulatory authorities or from the NHS Trust, where it is relevant to my taking part  
     in this research. I give permission for these individuals to have access to my  
     records.  
 
7.  I understand that by taking part, I am agreeing that the researchers may use  
     anonymous extracts from the transcripts of my audio/video -recordings and  

















 8.  I agree that anonymous extracts from the transcripts of my audio/video-recordings  
     can be used for training and teaching students and healthcare professionals.  
 
 9.  I agree that the researchers can use clips from my audio recording for the  
      teaching and training of students or healthcare professionals. I understand that  
      all identifying details (e.g. names, place names) will be deleted before the clips  
      are played and my name will not be used. 
 
10.  I agree that the researchers can use clips from my video recording for the  
      teaching and training of students or healthcare professionals. I understand that  
      all identifying details (e.g. names, place names) will be deleted before the clips  
      are played and my name will not be used. 
 
11.  I agree that my data gathered in this study may be stored (after it has been  
      anonymised) in Oxford Brookes University and may be used for future research.  
 
12.  I give consent for the research team to share anonymised written, video and  
      audio material collected in this study with other researchers. 
 









Name of researcher 
taking Consent: _____________________________________________________ 
 



















































FACIT Fatigue Scale (Version 4) 
English (Universal)  16 November 2007 
Copyright 1987, 1997  Page 1 of 1 
 
 
Below is a list of statements that other people with your illness have said are important. Please circle 















HI7 I feel fatigued ....................................................................  0 1 2 3 4 
HI12 I feel weak all over ............................................................  0 1 2 3 4 
An1 I feel listless (“washed out”) ..............................................  0 1 2 3 4 
An2 I feel tired..........................................................................  0 1 2 3 4 
An3 I have trouble starting things because I am tired.................  0 1 2 3 4 
An4 I have trouble finishing things because I am tired ..............  0 1 2 3 4 
An5 I have energy.....................................................................  0 1 2 3 4 
An7 I am able to do my usual activities.....................................  0 1 2 3 4 
An8 I need to sleep during the day ............................................  0 1 2 3 4 
An12 I am too tired to eat............................................................  0 1 2 3 4 
An14 I need help doing my usual activities .................................  0 1 2 3 4 
An15 I am frustrated by being too tired to do the things I want 




















































































Patient Information Sheet 
Understanding fatigue in patients with cancer or heart failure 
 
Invitation  
Thank you for taking part in the first stage of our research study and we would like to invite you 
to take part in the second stage. This is a PhD student project towards the thesis of John Curtin. 
This information sheet tells you about this. Please read it carefully and ask me if there is anything 
that is not clear or if you would like more information. Please take time to decide whether or not 
you wish to take part. Many thanks for reading this.  
What is the purpose of this study?  
We want to understand how fatigue (tiredness, exhaustion or low energy levels) affects the quality 
of life, the ability to undertake activities of everyday living and physical activity in patients living 
with cancer or heart failure. We also want patients to reflect on how they felt their doctor 
addressed their symptoms, in particular fatigue, in a recent hospital appointment. We want to 
understand what symptoms are important to patients and see if we can identify ways to improve 
communication between doctors and patients.  
Why have I been invited? 
You have been invited to take part because you have had your appointment with the doctor video-
recorded and you experience fatigue. We hope that around 30 - 40 patients will complete the 
second part of the study.  
Do I have to take part? 
No, it is entirely up to you. This information sheet should help you to decide whether you want to 
take part and we are happy to answer any questions you may have. You are free to withdraw at 
any time, without giving a reason. A decision to leave the study or to decline to be involved would 
not affect the standard of care you receive from the clinical team.    
What will happen to me if I take part? 
If you agree to take part, I will agree a convenient time for you to be interviewed in your own 
home. I will ask you to sign a consent form before the interview. This interview will be no longer 
that one hour long and it will be a discussion with you about your experience of living with cancer. 




















What are the possible benefits of taking part? 
The study may not have any direct benefits for you but it is hoped that the findings will help doctors 
to provide better support for patients in the future. The findings of the study may help doctors to 
improve the assessment and management of symptoms in patients with cancer or heart failure. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions (on phone number 01865 485278). If you remain 
unhappy and wish to raise questions about how the research is being conducted, you can contact 
Hazel Abbott, Departmental Research Ethics Officer, Faculty of Health and Life Sciences on 
01865 482639.  
Will what I say in this study be kept confidential? 
All information that is collected about you will be handled and kept strictly confidential, and any 
information about you will have your name and address removed so that you cannot be 
recognised. Your data can only remain confidential within the limitations of the law. Audio 
recordings will be sent to a professional transcribing team who have a duty to protect your 
confidentiality. All information (transcripts and consent forms) will be kept by the research team 
(John Curtin and Dr Helen Walthall) and stored securely in locked cupboards in a locked office at 
Oxford Brookes University. This information will be kept for 20 years for the purposes of writing 
up the study’s findings for publication and in order that the data can be reanalysed. After 20 years, 
all your information will be destroyed. This data will not have any identifying details.  
What should I do if I want to take part? 
I will ask for your permission to contact you in a few days time, in order to give you time to decide 
if you want to take part in this study. Alternatively, if you prefer, you can contact me by telephone 
or email. Please see the contact details at the end of this information sheet.  
What will be done with the information collected in the study? 
The findings will be published in scientific journals and presented at conferences and in training 
workshops. With your permission, we may use direct quotes from your interview in these papers, 
presentations and workshops. However, the quotes will be anonymous and your name will never 
be included in any paper or presentation. If you wish, we will send you a summary of the findings 
at the end of the study. This will be in about two years’ time. 












Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been approved by both the Oxford Brookes 
University Faculty Research Ethics Committee and the XXXXXXXXXX NHS Research Ethics 
Committee.  
 
Who should I contact with questions? 
If you have any questions about the study, please don’t hesitate to contact:   
 
John Curtin, PhD student, Faculty of Health & Life Sciences, Oxford Brookes University  
 
Telephone: 01865 485278 or email: john.curtin-2013@brookes.ac.uk	
 
 
Research and supervisory team from Oxford Brookes University includes:  
 
Dr Helen Walthall, Principal Lecturer, Faculty of Health and Life Sciences 
 
Prof Eila Watson, Professor in Supportive Cancer Care, Department of Clinical Health Care 
 
Dr Bee Wee, Consultant and Senior Lecturer in Palliative Medicine, Sobell House,  










































































Clinician Information Sheet 







Fatigue is a common and complex symptom in advanced cancer or chronic heart failure. Recent 
published systematic reviews reveal that there are few pharmacotherapy options that are 
potentially beneficial in these patient groups. This suggests that fatigue may be a difficult symptom 
for clinicians to manage in their patients. We want to explore what doctors feel are the challenges 
in the assessment and management of fatigue in patients with advanced cancer or chronic heart 
failure.  
The first part of the study involves the video-recording of patient-doctor consultations in oncology 
or heart failure clinics in several hospitals. The second part of the study involves interviewing 
patients and doctors.  
You have been invited because you are either a consultant cardiologist or oncologist, or a 
specialist trainee with at least 2 years’ experience. We would like to interview 30 to 40 clinicians 
in this study. 
It is up to you to decide to join the study. If you wish to hear more about the study or wish to take 
part please contact me by telephone or email, using my details at the end of this information sheet. 
You are free to withdraw at any time, without giving any reason.  
If you agree to take part, I will agree a convenient time for you to be interviewed in a place of your 
choosing. I will ask you to sign a consent form before the interview. The interview will last for 
approximately 30 minutes and with your permission, will be audio-recorded. It will be a discussion 
on your experiences and views on the assessment and management of fatigue in patients with 
advanced cancer or chronic heart failure. You are free to stop the interview at any time and for 
any reason.  
We hope the study may help to improve the assessment and management of symptoms in 
patients with advanced cancer or chronic heart failure. We do not foresee any risks to doctors 
My name is John Curtin and I am a PhD student at Oxford Brookes University. I am also a 
specialist trainee in palliative medicine on approved out of programme research experience 
from the XXXXXXXXXX Deanery.  
In association with the Oncology and Heart Failure clinical teams at XXXXXXXXXXX NHS 
Trust, we are conducting a research study about fatigue in advanced cancer or chronic heart 
failure. This research study will contribute towards my PhD thesis. 














The findings will be published in scientific journals and presented at conferences and in 
training workshops. With your permission, we may use direct quotes from your interview in 
these papers, presentations and workshops. However, the quotes will be anonymous and your 
name will never be included in any paper or presentation. If you wish, the findings of the study 
will be fed back to you in written form and where possible, will be presented at departmental 
or network research meetings.   
All information that is collected about you will be handled and kept strictly confidential, and 
any information about you will have your name removed so that you cannot be recognised. 
Your data can only remain confidential within the limitations of the law. Audio recordings will 
be sent to a professional transcribing team who have a duty to protect your confidentiality. All 
information will be kept by the research team (John Curtin and Dr Helen Walthall) and stored 
securely in locked cupboards in a locked office at Oxford Brookes University. This information 
will be kept for 20 years for the purposes of writing up the study’s findings for publication and 
in order that the data can be reanalysed. After 20 years, all your information will be destroyed. 
This data will not have any identifying details.  
The research is funded by Oxford Brookes University. The study has been approved by both 
the Oxford Brookes University Faculty Research Ethics Committee and the XXXXXXXXXX 
NHS Research Ethics Committee.  
 
If you have any questions about the study, please don’t hesitate to contact:   
 
Dr John Curtin, PhD student, Faculty of Health & Life Sciences, Oxford Brookes University 
Telephone: 01865 485278 or email: john.curtin-2013@brookes.ac.uk 
 
 
If you wish to raise questions about how the research is being conducted or complain 
formally, you can contact:  
 
Hazel Abbott, Departmental Research Ethics Officer, Faculty of Health & Life Sciences, OBU 
Telephone: 01865 482639 or email: heabbott@brookes.ac.uk 
 
 
Research and supervisor team from Oxford Brookes University includes:  
 
• Dr Helen Walthall, Principal Lecturer, Faculty of Health & Life Sciences 
• Prof Eila Watson, Professor in Supportive Cancer Care, Department of Clinical Health Care 
• Dr Bee Wee, Consultant and Senior Lecturer in Palliative Medicine, Sobell House,  
  Oxford University Hospitals NHS Trust 
 
 
Many thanks for your time in reading this leaflet and considering taking part 
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Appendix	3.14.	Clinician	interview	topic	guide	
	
	
	
	
	
	
	
FREC	study	number:	2013/16		
NRES	study	number:		
Study	title	–	Exploration	of	fatigue	in	advanced	cancer	and	chronic	heart	failure	
	
Topic	guide	for	doctor	interview		
	
1. Open	with	general	inquiry	on	clinician’s	experience	and	usual	patient	population		
2. Fatigue	in	patient	population		
3. Assessment	of	fatigue	
4. Communication	of	fatigue		
5. Interventions	for	fatigue		
6. Role	of	doctor		
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Appendix	14.1			Pen	portraits	of	participants	in	Part	B	
	
	
Sharon	
Sharon	was	a	retired	widow	and	lives	alone.	She	retired	to	care	for	her	husband	with	Motor	
Neuron	Disease	who	died	several	years	previously	at	home.	She	enjoyed	daily	exercise	and	
was	house	proud.	She	was	diagnosed	with	bowel	cancer	after	presenting	to	hospital	with	
bowel	obstruction	and	then	had	curative	surgery	followed	by	a	short	trial	of	adjuvant	oral	
chemotherapy.	About	8	months	later,	she	was	diagnosed	with	metastatic	cancer	and	started	
palliative	chemotherapy,	planned	8	cycles,	with	the	possibility	of	surgical	liver	resection.	The	
interview	took	place	several	days	after	her	5th	cycle	of	treatment.	She	described	transient	
physical	fatigue	which	lasted	several	days	post	chemotherapy.	
	
Stephen	
Stephen	lived	with	his	second	wife	and	young	daughter.	He	was	self-employed	and	his	wife	
worked	part-time.	He	was	diagnosed	with	metastatic	colon	cancer	and	underwent	surgical	
excision	of	the	primary	tumour	followed	by	palliative	systemic	chemotherapy	about	2	years	
previously.	He	received	almost	continuous	chemotherapy	in	the	intervening	period	due	to	
disease	progression	whenever	treatment	was	withdrawn.	His	maintenance	cancer	treatment	
regimen	contributed	to	gradually	progressive	fatigue	over	the	previous	6-12	months.	At	
recent	clinic	review,	the	Oncologist	temporarily	stopped	his	oral	chemotherapy	to	facilitate	
recovery	from	a	viral	illness	and	help	fatigue.	He	was	interviewed	several	weeks	after	a	
pause	in	oral	chemotherapy.		He	described	constant	severe	physical	and	mental	fatigue.		
	
Cecil		
Cecil	lived	with	his	wife	and	she	performed	all	the	household	tasks.	He	had	a	strong	faith	and	
believed	in	the	power	of	prayer.	He	had	radical	surgery	for	prostate	cancer	about	10	years	
ago	and	he	felt	fatigue	gradually	started	after	this.	Ever	since	then,	on	medical	advice,	he	
had	a	daily	afternoon	nap	which	he	found	helpful.	He	was	diagnosed	with	colorectal	cancer	
2	years	ago,	with	emergency	surgery	followed	by	adjuvant	chemotherapy.	Metastatic	liver	
disease	was	confirmed	over	a	year	later	and	since	then,	he	has	received	2	lines	of	palliative	
chemotherapy	treatment.	His	most	recent	treatment	dose	was	reduced	by	the	Oncologist	
due	fatigue	and	he	was	interviewed	about	5	days	after	his	final	cycle.	He	described	transient	
severe	physical	fatigue.	He	died	around	6	months	later.	
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Michael		 	
Michael	was	single	and	had	always	lived	with	his	parents.	His	father	had	dementia	with	poor	
short	term	memory	and	he	helped	his	mother	with	maintaining	the	household.	He	had	
always	thought	that	he	would	be	looking	after	them	in	old	age	until	their	death.	He	enjoyed	
sport	and	had	always	been	an	active	person,	walking	twice	daily.	About	a	year	ago,	he	was	
diagnosed	with	metastatic	colorectal	cancer	with	liver	disease	after	presenting	with	
abdominal	pain.	He	was	on	his	second	line	of	palliative	systemic	chemotherapy	with	
alterations	in	his	treatment	schedule	due	to	bone	marrow	suppression.	The	day	before	the	
interview,	his	chemotherapy	was	cancelled	for	this	very	reason.	He	felt	he	could	do	only	half	
of	what	he	could	do	previously.	He	died	within	a	year	of	the	interview.		
	
Conor	
Conor	lived	with	his	wife,	step-son,	daughter-in-law	and	baby	grandchild.	He	had	retired	
within	the	last	year	when	he	was	diagnosed	with	cancer.	He	had	always	been	an	active	
person	and	enjoyed	exercising.	He	was	diagnosed	with	metastatic	colorectal	cancer	with	
lung	disease	after	a	delayed	presentation	with	rectal	bleeding.	He	had	a	palliative	colostomy	
followed	by	downsizing	chemo-radiotherapy	which	the	disease	progressed	on.	He	was	
receiving	second	line	palliative	chemotherapy	and	was	hopeful	for	a	surgical	stoma	reversal	
if	he	responded	to	treatment.	He	was	interviewed	after	his	4th	cycle	of	chemotherapy	and	
his	wife	was	present	throughout	the	interview.	He	described	constant	physical	and	mental	
fatigue.	He	died	within	a	year	of	the	interview.	
	
Gordon		
Gordon	was	married	and	lived	with	his	wife.	He	worked	as	a	self-employed	contractor	in	the	
same	factory	as	his	wife.	He	absence	was	difficult	for	them	financially	and	in	the	workplace.	
He	was	diagnosed	with	inoperable	pancreatic	cancer	after	presenting	with	diabetes	mellitus	
and	obstructive	jaundice	about	4	months	previously.	He	was	receiving	palliative	
chemotherapy	with	the	possibility	of	12	scheduled	cycles.	The	interview	occurred	after	his	
5th	cycle	of	treatment.	Because	of	treatment	related	side	effects	which	included	severe	
fatigue,	the	chemotherapy	dose	was	reduced	on	several	occasions.	He	described	severe	
transient	physical	and	mental	fatigue	lasting	for	around	5	days	after	each	cycle.	He	died	
within	a	year	of	the	interview.	
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Brian		 	
Brian	was	single,	lived	alone	and	his	sister	lived	nearby.	He	was	diagnosed	with	inoperable	
pancreatic	cancer	nearly	4	years	previously.	Initially,	he	had	a	clinical	trial	cancer	treatment,	
followed	by	systemic	palliative	chemotherapy	and	then	chemo-radiotherapy.	He	was	
scheduled	for	a	re-challenge	of	treatment	with	the	possibility	of	12	cycles	scheduled.	He	was	
interviewed	after	his	3rd	cycle.	Because	of	treatment	related	side	effects	which	included	
severe	fatigue,	the	chemotherapy	dose	was	reduced	and	the	dose	interval	between	cycles	
was	increased	to	3	weekly.	He	described	severe	transient	physical	and	mental	fatigue	lasting	
around	7	days	after	each	cycle	followed	by	constant	moderate	fatigue.	Since	this	treatment	
began,	he	very	much	depended	on	his	sister	and	her	husband.	He	died	within	6	months	of	
the	interview.	
	 	
Clive		 	
Clive	was	married	and	lived	with	his	wife.	He	retired	at	the	age	of	75	years.	He	was	
diagnosed	with	a	sigmoid	tumour	with	metastatic	lung	disease	about	3	years	previously	and	
then	received	palliative	chemotherapy.	Almost	1	year	ago	he	underwent	a	palliative	surgical	
ileostomy	followed	by	pelvic	radiotherapy.	Recently	he	started	a	new	line	of	palliative	
systemic	chemotherapy	treatment	and	was	interviewed	after	the	2nd	cycle.	He	described	
constant	moderate	physical	fatigue	which	he	felt	had	improved	since	the	commencement	of	
treatment.	He	died	within	6	months	of	the	interview.	
	
Eileen	 	
Eileen	was	single	and	lived	in	a	residential	care	home	for	some	years.	She	was	a	retired	
teacher	and	over	the	years	her	activity	levels	had	declined.	She	was	diagnosed	with	a	rectal	
tumour	after	presenting	with	rectal	bleeding	about	9	months	ago.	She	received	downsizing	
radiotherapy	but	disease	progressed	and	she	metastatic	lung	disease	was	confirmed.	She	
was	then	commenced	on	reduced	dose	oral	palliative	chemotherapy	and	recent	scans	
confirmed	stable	disease.	She	described	constant	moderate	physical	fatigue	which	worsened	
on	treatment.	She	died	within	6	months	of	the	interview.	
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Shay	 	
Shay	was	married	and	lived	with	his	wife	and	son.	He	was	a	retired	painter	decorator.	He	
presented	almost	3	years	previously	with	a	rectal	tumour	and	declined	surgery,	preferring	
radical	chemo-radiotherapy	instead.	Following	this	he	had	further	chemotherapy	followed	
by	surgical	excision	of	tumour	with	stoma	formation.	Restaging	scans	one	year	later	
confirmed	local	recurrence	and	metastatic	lung	disease.	He	received	a	further	re-challenge	
of	palliative	systemic	chemotherapy	and	was	on	surveillance	follow	up	at	the	oncology	clinic.	
He	was	interviewed	3	months	after	completing	treatment.	Overall	his	physical	ability	had	
deteriorated	over	the	preceding	3	years	but	he	was	able	to	do	some	gardening.		
	
Claire		
Claire	was	married	and	lived	at	home	with	her	husband	who	had	Parkinson’s	disease.	They	
were	both	retired	and	had	3	grown	up	boys	together.	She	had	a	colonic	carcinoid	tumour	
excised	4	years	ago	and	lung	nodules	were	then	confirmed	on	re-staging	scans	2	years	later.	
Surgical	excision	of	lung	nodules	confirmed	lung	cancer	and	she	received	adjuvant	
chemotherapy.	Recurrent	lung	disease	was	confirmed	several	months	later	and	she	
completed	a	further	course	of	palliative	systemic	chemotherapy.	Recent	clinic	review	and	
investigations	confirmed	stable	disease.	She	was	interviewed	6	months	after	finishing	
treatment	and	in	the	company	of	her	husband.	She	described	constant	severe	fatigue.		
	
Sonya		
Sonya	was	widow	and	lived	alone.	She	was	a	retired	teacher	and	had	lost	her	daughter	the	
year	previously	due	to	a	long	illness	with	Multiple	Sclerosis.	She	was	club	captain	in	her	golf	
club	and	tried	to	keep	up	with	her	commitments.	She	presented	with	metastatic	colorectal	
cancer	with	liver	disease	about	15	months	previously.	In	the	interim	she	had	2	lines	of	
palliative	systemic	chemotherapy.	She	was	interviewed	about	3	weeks	after	completing	the	
final	cycle	of	chemotherapy	scheduled.	She	described	constant	moderate	fatigue.		
	
Daniel		
Daniel	was	married	and	lived	at	home	with	his	wife.	He	was	a	retired	management	
consultant	and	practiced	management	by	objectives.	For	many	years,	he	had	a	daily	exercise	
routine	devised	by	the	Canadian	Air	Force	and	was	quite	active.	He	was	diagnosed	with	
mesothelioma	around	6	months	previously	after	presenting	with	breathlessness	and	a	
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pleural	effusion.	He	received	palliative	systemic	chemotherapy	and	his	treatment	dose	was	
reduced	due	to	severe	fatigue.	At	recent	clinic	review,	disease	progression	was	confirmed	
and	treatment	was	stopped.	He	was	interviewed	about	5	weeks	after	stopping	treatment	
and	was	awaiting	to	be	seen	in	the	phase	1	clinical	trials	unit.		
	
Larry		
Larry	was	married	and	lived	at	home	with	his	wife.	He	was	a	retired	heavy	goods	vehicle	
driver	and	had	multiple	co-morbidities	with	continuous	home	oxygen	in	place.	He	was	a	
keen	gardener	and	previously	managed	3	allotments	in	the	past.	He	was	diagnosed	with	
metastatic	lung	cancer	after	a	fall	resulted	in	a	fractured	neck	of	femur	which	required	
surgical	repair	about	8	months	previously.	In	the	interim	he	had	palliative	radiotherapy	to	
his	femur	and	lung.	He	was	not	fit	enough	for	palliative	chemotherapy	and	his	symptoms	
were	monitored	in	the	clinic.	At	recent	clinic	review,	he	was	treated	for	an	infective	
exacerbation	of	chronic	obstructive	pulmonary	disease.	He	was	interviewed	in	the	company	
of	his	wife.	He	described	constant	moderate	fatigue.		
	
Tom	
Tom	lived	with	his	wife	in	an	apartment	in	an	independent	shared	living	retirement	complex.	
He	was	a	retired	fireman	and	previously	enjoyed	being	active.	He	was	diagnosed	with	
metastatic	oesophageal	cancer	with	liver	disease	4	months	ago.	He	then	commenced	on	
palliative	systemic	chemotherapy	with	a	projected	schedule	of	6	cycles.	He	was	interviewed	
a	couple	of	weeks	after	his	5th	cycle	and	his	wife	was	present	throughout.	He	described	
severe	transient	fatigue	which	was	modestly	improving	at	the	time	of	the	interview.	He	died	
within	a	year	of	the	interview.	
	
Pandora		
Pandora	was	married	and	lived	with	her	husband.	She	worked	part-time	as	an	administrator,	
while	he	was	retired	from	finance	and	they	had	3	adult	children	together.	She	presented	
with	symptomatic	anaemia	nearly	2	years	previously	and	had	emergency	surgery	for	a	
colonic	tumour	followed	by	adjuvant	chemotherapy.	Relapse	disease	was	confirmed	about	1	
year	later	and	in	the	interim	she	completed	11	cycles	out	of	a	scheduled	12.	She	was	
interviewed	over	2	months	after	completing	this	treatment	and	her	constant	moderate	
fatigue	had	improved	considerably.	She	died	within	a	year	of	the	interview.	
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Jane	
Jane	was	divorced	and	lived	alone	in	a	flat.	She	was	a	retired	housekeeper	and	had	one	
daughter	who	lived	a	distance	away.	She	was	diagnosed	with	breast	cancer	and	had	a	
mastectomy	8	years	previously.	Staging	scans	confirmed	extensive	metastatic	bone	disease	
and	she	then	completed	a	course	of	palliative	systemic	chemotherapy.	In	the	intervening	
period,	she	had	several	different	hormone	blockade	therapies	and	more	recently	a	trial	of	
oral	chemotherapy.	At	the	clinic	review,	the	Consultant	stopped	her	oral	chemotherapy	due	
to	deteriorating	performance	status	and	end	of	life	discussions	took	place.	She	described	
constant	severe	fatigue.	She	died	within	2	months	of	the	interview.	
	
Chloe		
Chloe	was	married	and	lived	with	her	husband.	She	was	retired	from	paid	work	and	was	
close	to	her	2	adult	children	who	lived	nearby.	She	had	abdominal	surgery	to	repair	a	hernia	
about	a	year	previously	and	to	avail	of	surgery,	she	was	obliged	to	significantly	alter	her	
lifestyle	by	losing	weight	and	exercising	daily.	Several	months	later,	she	was	diagnosed	with	
metastatic	breast	cancer	with	nodal	and	lung	disease,	after	presenting	with	breathlessness	
related	to	pulmonary	emboli.	She	was	scheduled	for	6	cycles	of	palliative	systemic	
chemotherapy	and	was	interviewed	several	days	after	her	final	cycle.	She	described	severe	
transient	fatigue.		
	
Clodagh		
Clodagh	was	a	single	mother	and	lived	on	her	own.	She	worked	as	an	English	teacher	in	a	
school	for	children	with	special	needs	and	her	daughter	was	attending	college.	She	was	
diagnosed	with	metastatic	breast	cancer	with	extensive	bone	disease	nearly	5	months	
previously	and	was	scheduled	to	complete	6	cycles	of	palliative	systemic	chemotherapy.	She	
was	interviewed	several	days	after	her	final	cycle.	She	described	moderate	constant	fatigue.		
	
Peggy		
Peggy	was	divorced	and	lived	on	her	own.	She	was	a	retired	historian	and	artist.	She	enjoyed	
spending	time	with	her	2	remaining	children	and	several	grandchildren.		She	was	diagnosed	
with	breast	cancer	around	18	years	ago	and	had	a	mastectomy	followed	by	adjuvant	
chemotherapy.	Relapse	metastatic	bone	and	lung	disease	was	confirmed	several	years	ago.	
In	the	intervening	period,	she	had	hormone	blockade	therapy	and	more	recently	was	
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commenced	on	a	clinical	trial	with	combination	oral	hormone	blockade	and	targeted	
therapy.	Cancer	treatment	was	paused	after	she	developed	pneumonia	and	was	admitted	to	
hospital.	She	was	interviewed	several	weeks	after	discharge.	She	described	moderate	
constant	fatigue.	
	
Gloria		
Gloria	was	married	and	lived	with	her	husband.	She	was	a	retired	healthcare	professional.	
She	was	diagnosed	with	breast	cancer	around	15	years	ago	and	had	surgery	followed	by	
adjuvant	hormone	blockade	therapy.	Relapse	metastatic	liver	and	bone	disease	was	
confirmed	one	year	ago,	after	she	presented	with	cauda	equina	syndrome.	She	initially	had	
palliative	systemic	chemotherapy	but	this	was	stopped	after	2	cycles	due	to	severe	side	
effects.	In	the	intervening	period,	she	had	hormone	blockade	therapy	and	more	recently	
was	commenced	on	palliative	systemic	chemotherapy.	Cancer	treatment	was	paused	after	
she	developed	pneumonia	and	was	admitted	to	hospital.	She	was	interviewed	over	a	month	
after	discharge.	She	described	constant	severe	fatigue.	She	died	around	6	months	after	the	
interview.	
	
Mary		
Mary	was	single	and	lived	in	a	shared	living	space	with	her	sister	and	her	family.	She	was	a	
retired	office	worker	and	had	a	long	history	of	mental	health	illness	including	anxiety	and	
depression.	She	was	diagnosed	with	inflammatory	breast	cancer	1	year	previously	and	
underwent	neo-adjuvant	chemotherapy	prior	to	surgery	which	was	then	followed	by	
adjuvant	radiotherapy.	She	was	diagnosed	relapsed	metastatic	skin	and	bone	disease	some	
months	later.	She	was	commenced	on	oral	chemotherapy	with	a	projected	schedule	of	6	
cycles.	She	was	interviewed	after	her	4th	cycle.	She	described	constant	moderate	fatigue.		
	
	
